Antares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $13.96 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.